• Users Online: 312
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 19  |  Issue : 4  |  Page : 230-233

A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study


1 Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India
2 Department of Medical Intern, Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India
3 Scientist D (Medical), ICMR-National Centre for Disease Informatics and Research, Bangalore, Karnataka, India
4 Department of Community Medicine, Akash Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India

Correspondence Address:
Dr. Hulugappa Lakshmi
Department of Community Medicine, Akash Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/am.am_92_22

Rights and Permissions

Introduction: COVID-19 virus caused a pandemic in 2020. Since vaccine was the only modality to combat the pandemic, the development of vaccine was fast tracked and made available within 1 year of detecting the virus. Objective: The objective of this study was to assess the safety and clinical efficacy of the COVID-19 vaccines. Materials and Methods: This was a cross-sectional study conducted between June 2021 and September 2021 in Bengaluru using digital data capture. Data pertaining to sociodemographic profile, details of the vaccine administered, adverse events developing within 7 days of vaccine administration, and breakthrough infection were collected. Descriptive statistics such as frequencies, percentages, and mean and standard deviation were used. Inferential statistics such as the Chi-square test were used to test association. Results: The study involved 103 study participants. Totally 100 (97.08) participants had taken Covishield and 3 (2.92) had taken Covaxin. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Ninety-four (91.26%) of study participants had taken at least one dose of COVID-19 vaccine. A total of 62 (60.19%) participants had one or the other adverse reaction following vaccination. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Conclusion: The given COVID-19 vaccines are safe and clinically efficacious with no statistically significant difference between the COVID-19 vaccine type and adverse reaction or with the incidence of breakthrough infection.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed443    
    Printed34    
    Emailed0    
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal